Acquired brain injury (ABI) -whether due to stroke, trauma or any other cause -is frequently complicated by depression, which can interfere with rehabilitation, leading to poorer outcomes. The use of antidepressants in the treatment of depression following ABI is increasingly widespread. Because it may not be practical to involve a psychiatrist in all cases, first line management is usually undertaken by general clinicians. However, at present, many people are given antidepressant medication as a matter of routine -often without their knowledge and without any clear treatment plan.
Introduction and aims
Acquired brain injury (ABI) -whether due to stroke, trauma or any other cause -is frequently complicated by depression, which can interfere with rehabilitation, leading to poorer outcomes. The use of antidepressants in the treatment of depression following ABI is increasingly widespread. Because it may not be practical to involve a psychiatrist in all cases, first line management is usually undertaken by general clinicians. However, at present, many people are given antidepressant medication as a matter of routine -often without their knowledge and without any clear treatment plan.
The aim of these guidelines is to provide the general physician, GP or other clinician with a safe approach to managing minor to moderate depression in the context of rehabilitation or recovery from ABI, and to identify those individuals who require referral to mental health services.
The guidelines focus on the use of antidepressant drugs, but these are by no means the only way to manage depression following ABI, and it is important in any event to consider other contributing factors before reaching for the prescription pad. Alternative interventions may include simple measures to address environmental or other factors which contribute to low mood (such as missing their home and family, or worries about life outside hospital), and non-pharmacological interventions, such as 'talking therapies' , for patients who have the cognitive and communicative abilities to engage successfully.
The guidelines have been prepared in accordance with the principles laid down by the AGREE Collaboration (Appraisal of Guidelines for REsearch and Evaluation). 1 A summary of the guideline development process is given in Table 1 . Although developed specifically with brain injury in mind, the main principles applied here may also be applicable in other conditions, especially where the person's ability to interact is impaired.
G An emotional response to the sudden onset of disability and its associated life changes.
G A direct result of the brain injury leading to altered biochemical balance within the brain and resulting change in the background level of mood.
G Preceding tendency to depression or history of depressive illness.
Reasons why symptoms that mimic depression may occur following ABI
G Other emotional disorders associated with brain injury, such as apathy or emotional lability, may give the appearance of depression.
G Somatic symptoms which characterise depression in the normal population may occur as a result of hospitalisation or from the brain injury itself. These symptoms may include: -loss of energy, appetite and libido -altered sleeping habits -poor concentration, inability to make decisions, etc.
G Abnormal physical expressions of emotional status may give the appearance of depression, eg: -disorders of facial expression -flat speech patterns -general physical slowness.
The aetiology of depression in acquired brain injury
Reported frequencies of depression following ABI vary, but are generally around 30-40%. [2] [3] [4] [5] [6] [7] Depression may remit between one and two years after injury, [8] [9] [10] at least in a proportion of cases. The aetiology of depression in the context of ABI is often multifactorial, and it is important to understand the reasons why it occurs in order to determine the circumstances in which antidepressants may or may not help (see Box 1) . Antidepressants may be helpful for depression, and possibly other mood disorders such as emotional lability, but are unlikely to be helpful where clinical features of the brain injury itself mimic depression.
Diagnosis and measurement of depression
The possibility of depression should be considered in all patients following ABI. Screening and assessment of depression, however, carries no benefit if it is not followed through to appropriate treatment planning and continued monitoring to ensure response. A number of measures have been developed to quantify depression. These exist in several different formats which may be chosen to suit the patient's capabilities in response. Whatever the assessment process used, it must be timely and practical to allow for repeat use on subsequent occasions for comparison. The fuller version of this guidance (see end of paper) provides a more detailed account of the various scales available, but three simple and freely available scales are presented here for basic screening in clinical settings. These are:
• Depression Intensity Scale Circles (DISCs) 11
-a simplified visual analogue scale specifically designed for people with communication or cognitive difficulties, but who have adequately preserved visuospatial skills (Fig 1) .
• The Short-Form Geriatric Depression Scale (GDS-15) 12* -a simple questionnairebased tool for people with adequate verbal and language skills (Box 2). 
Scope and purpose
Overall objective of To clarify the main indications and contraindications to the the guidelines use of antidepressants and provide guidance on a safe approach to managing mild to moderate degrees of depression in the context of recovery and rehabilitation following acquired brain injury (ABI).
The patient group
Adults with ABI of any cause, including stroke and other covered vascular injury, trauma, inflammation/infection, anoxia etc, who present with depression or low mood in the context of recovery or rehabilitation in inpatient or community settings.
Target audience
General physicians, GPs and other clinicians involved in the management and rehabilitation of patients with ABI.
Clinical areas
G Screening and assessment of depression in the context covered of ABI G Selection of patients for whom antidepressants are appropriate G Providing information and obtaining informed consent G Treatment planning and monitoring, including withdrawal G Which patients to refer for formal psychiatric advice.
Stakeholder involvement The Guideline
A multidisciplinary working party representing: Development Group G physicians practising in stroke medicine, and (GDG) rehabilitation for adults across the age ranges G liaison psychiatry, neuropsychiatry, clinical neuropsychology G primary care G representatives of patients and user groups.
Funding
The project was jointly funded by the British Society of Rehabilitation Medicine (BSRM) and the British Geriatrics Society (BGS).
Conflicts of interest
Conflicts of interest were fully declared and are summarised in Appendix 1 of the fuller version of this guidance.
Rigour of development
Evidence gathering Evidence for these guidelines was provided by review of Cochrane Library, Medline, Embase, conference proceedings and other guidelines up to October 2004. Articles not published in English were excluded. As part of the guideline development, a survey of consultant members of the BSRM and BGS was undertaken to establish current practice in the UK regarding the use of antidepressant medication in the context of rehabilitation following ABI. 23 
Review process
The evidence was evaluated by members of the GDG.
Links between
The system used to grade the evidence and guidance evidence and recommendations is that published by the Royal College recommendations of Physicians. 26 In the absence of specific research evidence on which to base the detailed advice, all recommendations in this set of guidelines are graded at level C.
Piloting and
Not yet piloted. peer review Implementation Tools for application Tools for implementation are included in the fuller version of this guidance.
Plans for update
The guidelines will be reviewed in 2008.
• The Signs of Depression Screening Scale (SDSS) 13 -a simple tool based on observation of behaviour such as crying, withdrawal, or apathy which may be useful where the individual is unable to respond to either of the above (Box 3).
More detailed assessment is then required for those in whom depression is suspected, to distinguish symptoms of depression from the general effects of ABI, and to quantify the severity of depression prior to considering treatment. A schema for assessment is outlined in Fig 2. 
Capacity and consent
The capacity to consent to treatment requires the patient to be able to: (a) understand and retain information about the treatment proposed and any alternative options that may be available, and (b) weigh up the benefits and risks associated with treatment, including any possible consequences of declining treatment. • The grey circles show how depressed you feel.
[Indicate the clear circle at the bottom] • The bottom circle shows no depression.
[Indicate the fully shaded circle at the top] • The top circle shows depression as bad as it can be.
[Pointing at each circle in ascending order] • As you go from the bottom circle to the top, you can see that depression is becoming more and more severe.
• Which of these circles shows how depressed you feel today?
To the administrator:
In your opinion was the person able to understand this scale?
Yes No Comment Box 3. Signs of Depression Screening Scale (SDSS). 13 1 People who have ABI may have cognitive and communicative difficulties that limit their capacity to make informed decisions about their treatment and to give consent, or their judgement may be clouded by the depression itself. In these situations, assessment may be complex and formal psychiatric advice may be required.
Even when patients can give consent, they may feel uncertain about why treatment is being recommended. Every effort should be made to provide the right information at the right time and in an accessible format (see fuller version for sample information sheet).
The evidence for use of antidepressants in people with ABI
Systematic review and assimilation of the evidence for use of antidepressants in ABI is confounded by heterogeneity in research design, time-points of measurement and instruments used to assess depression. Most studies to date have examined short-term effects only, with no standardised assessment of adverse effects. There is little or no formal research-based evidence to date to inform the most appropriate regimen or length of treatment. However, the following general conclusions may be drawn from the literature:
• Antidepressants are reasonably safe and acceptable to patients, but probably less effective than originally supposed. Overall, approximately four patients would need to be treated to produce one recovery, and one in ten patients would drop out because of side-effects. 14 • All antidepressant drugs lower the threshold for seizures, which is a particular concern in the context of ABI.
• Improvement in symptoms of depression or lability is often reported, [15] [16] [17] [18] [19] but actual gains in function or quality of life are harder to demonstrate. 20 • Selective serotonin re-uptake inhibitors (SSRIs) appear generally to be about as effective as tricyclic antidepressants (TCAs), but have fewer reported side-effects, 21 and are probably therefore cost efficient despite the slightly higher drug costs. 22 Table 2 . Concise guidelines on the use of antidepressant medication following acquired brain injury. These guidelines are summarised in Fig 3. Grade of recommendation 1 Screening * C
Use of antidepressant medication following acquired brain injury

Clinical Medicine
The possibility of depression should be considered for any patient with acquired brain injury. G At the very least the patient should be asked 'Do you often feel sad or depressed?' at each assessment. G For individuals who are unable to respond, staff should consider whether their behaviour suggests depression (eg apathy, withdrawal, non-compliance, excessive crying etc). G Assessment should include inquiry for prior psychiatric history or any previous use of antidepressant medication, and should take into account previous personality and emotional traits, and change from normal personality. G The cause of apparent distress should be explored with the patient by an appropriate professional.
More detailed assessment of mood * C
For patients in whom depression is suspected, more detailed assessment of mood should be undertaken: G using validated instruments, interview and/or observation G to determine the severity of depression and contributing factors. 
Grade of recommendation
e Repeat assessment of mood after 6-8 weeks (using the same measure as in (a)) to assess the effect f In the case of a positive treatment response, an agreed treatment plan outlining: -length of treatment (usually 6 months) -procedure for withdrawal at the end of treatment and who will supervise this. g If the response to an appropriate dose of medication is poor or absent at 6-8 weeks, the drug should be withdrawn and alternative treatment or referral considered.
During treatment C
G Patients should see their doctor regularly during treatment (at least every 2 months) and any clinical deterioration during treatment should be investigated. In particular, the following should be considered as possible side-effects of treatment: -hyponatraemia, seizures, GI bleeding, anti-cholinergic symptoms, sexual dysfunction, sedation, hallucinations, increased confusion, headache.
G Antidepressant medication should not be given under automatic repeat prescription, and no more than 2 months supply should be given in any prescription.
Referral for formal psychiatric review C
The patient should be referred for formal psychiatric review if: G Depression is very severe or resistant to treatment G There is a past history of psychiatric disorder G The patient shows evidence of suicidal ideation or intent -this should trigger emergency referral G It seems likely that the patient needs to be treated under section of the Mental Heath Act 1983 or equivalent.
Withdrawal from treatment C
At the end of the treatment period (4 to 6 months) there should be a planned withdrawal of antidepressant medication, which should be undertaken gradually over a period of 1 to 2 months.
Prior to withdrawal: G The patient's mood should be re-evaluated using the same measure as at baseline G The patient/family should be warned to expect rebound symptoms.
In the event of significant longer-lasting relapse of depression, the need for long-term treatment should be considered and formal psychiatric advice sought.
• TCAs, however, may still have a role, particularly in the presence of symptoms such as neuropathic pain, hyper-salivation or insomnia, where their 'side-effects' may actually be desirable. 23 
Choice of antidepressant
There are important pharmaco-kinetic differences between the six SSRIs currently available, notably in their ability to inhibit hepatic cytochrome P450 iso-enzymes which are responsible for the metabolism of many drugs. 24 Citalopram and sertraline are among the more specific agents and in vitro studies suggest they are least likely to inhibit these iso-enzymes. A recent survey of rehabilitation consultants and geriatricians in the UK 23 has demonstrated these two agents to be the most common first choice for management of depression following ABI at present. More detailed information about the choice of antidepressant is given in the fuller version. Recent preliminary data in non-brain-injured patients suggest that St John's Wort may be as effective and better tolerated than paroxetine, but there is as yet no data on patients with ABI, or in comparison with the more specific agents which are preferred in this context. 25 
The guidelines
The guidelines are laid out in Table 2 and summarised systematically in Fig 3 . Table 2 ). *Response to SSRIs is often seen within 1-2 weeks of starting treatment, but TCAs may take longer to have effect. 
Screen for depression
Start antidepressant
